Please ensure Javascript is enabled for purposes of website accessibility

3 Stocks to Get on Your Watchlist

By Sean Williams – Updated Apr 7, 2017 at 6:08PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Are these three stocks set up for a large move?

I follow quite a lot of companies, so the usefulness of a watchlist to me cannot be overstated. Without my watchlist, I'd be unable to keep up on my favorite sectors and what's really moving the market. Even worse, without my watchlist, I'd be lost when it came time to choose what stock I'm buying or shorting next.

I'm making every Wednesday "Watchlist Wednesday," when I'll discuss three companies that have crossed my radar in the past week and at what point I may consider taking action on these calls with my own money. Keep in mind, these aren't concrete buy or sell recommendations, nor do I guarantee I'll take action on the companies being discussed weekly. What I can promise is that you can follow my real-life transactions through my profile, and that I, like everyone else here at The Motley Fool, will continue to hold the integrity of our disclosure policy in the highest regard.

MAP Pharmaceuticals (Nasdaq: MAPP)
The day of reckoning came for MAP shareholders this week, and it wasn't nearly as bad as many had predicted. The company's promising orally inhaled migraine treatment candidate, Levadex, failed to gain approval by the FDA, but it wasn't due to efficacy or adverse side effects. The real concerns were related to the chemistry, manufacturing, and control of the treatment, which should be easily remedied. While delayed, this drug looks like a near-lock for future approval once MAP addresses these issues.

MAP has a collaborative agreement in place with Allergan (NYSE: AGN) that will allow Allergan the licensing rights to Levadex within the United States. In return, MAP has already received $60 million in up-front payments and is on pace to receive another $77 million from a future Levadex approval, its first approved sale, and sales milestones thereafter. With ample cash in place, MAP is a biotech that should remain on your radar.

Peabody Energy (NYSE: BTU)
There's nothing I enjoy more sometimes than playing the contrarian, and nothing is more contrarian at the moment than jumping on the coal bandwagon.

Coal has had myriad issues over the past few months. China, which is a prime consumer of coal, has exhibited a notable contraction in manufacturing growth and coal prices themselves haven't been favorable. Then, last week, Peabody warned that because of torrential rains and the subsequent flooding of its mines in Australia that ensued, its operations have been affected, which will result in the company coming in at the low end of its original first-quarter forecast of $0.50-$0.75 of earnings per share.

I see this weakness as just another buying opportunity for what continues to be a long-term play on the United States' growing demand for energy. Coal constitutes nearly half of all energy production in the U.S., and Peabody is responsible for producing 10% of all coal used in electrical generation in the United States. Even with lowered projections, it's difficult to ignore Peabody while it's yielding 1.1% and trading at a mere seven times forward earnings.

Lennar (NYSE: LEN)
I still feel like the last housing bear on planet Earth, but Lennar may have just shoved itself ahead of the remaining bottom-feeders in the sector. Yesterday's earnings report from the company showed that its new orders rose 33% and marked the fourth-straight rise in new orders from the company. Although their homes price right around the same mark, the same couldn't be said of KB Home (NYSE: KBH), which bombed last quarter as it attempted to raise its prices too early and lost its primary mortgage provider during the quarter.

The key to Lennar's success has been its superior gross home margin which is by far and away the highest in the sector. This isn't to say that these other homebuilders won't turn a profit; it's just that Lennar is doing much more with their bottom dollar. I continue to feel though, that Lennar and all homebuilders are priced for perfect performance and would look to avoid the sector altogether.

Foolish roundup
Is my bullishness or bearishness misplaced? Share your thoughts in the comments section below, and consider following my cue by using the links below to add these three companies to your free personalized watchlist to keep up on the latest news with each company.

Don't let your search for great stocks end here. Consider getting your copy of our latest special report: "The Motley Fool's Top Stock for 2012." This report details a company that our chief investment officer has described as the "Costco of Latin America," and it's yours for the low, low price of free -- so don't miss out!

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. He's a total nerd when it comes to making lists. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy that believes transparency comes first.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Peabody Energy Corporation Stock Quote
Peabody Energy Corporation
Lennar Corporation Stock Quote
Lennar Corporation
$78.16 (4.84%) $3.61
KB Home Stock Quote
KB Home
$27.31 (5.36%) $1.39

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.